Haemonetics opened higher at $120.78, compared with its previous close of $120.54. In the last trading session, the stock traded between $119.45 and $124.00. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Haemonetics is now worth
$ 207.85
Giving a profit of
$ 107.85 (107.85%)
Note: Past profits do not guarantee future returns.
Rating from 9 Analysts
Today's Change
+$2.17 (+1.80%)
Day High
$124.00
Day Low
$119.45
Day Open
$120.78
Prev Close
$120.54
Volume
4,26,830
1W Return
-3.69%
1M Return
0.54%
3M Return
40.71%
6M Return
134.90%
1Y Return
71.08%
Market Cap ($ Mn)
5,588
PE Ratio
50.22
PB Ratio
5.65
PEG Ratio
4.73
ROE
18.75%
ROCE
10.48%
EPS (TTM)
$1.02
1 Week
-3.69%
1 Month
0.54%
3 Months
40.71%
6 Months
134.90%
9 Months
113.42%
Barrington Research raises Haemonetics price target to $145
Barrington Research raised Haemonetics Corp's price target to $145. The new target is a $5 increase from the previous level of $140. Analyst Michael Petusky maintained an Outperform rating on the stock.
6 days agoHaemonetics Q2FY27 Results: Organic revenue up 10%, EPS rises 6% to $1.35
Organic revenue grew 10% YoY in Q2FY27, driven by 18% growth in plasma collections. Adjusted EPS rose 6% to $1.35, while adjusted operating margin dipped 40 bps to 26.3%. Fiscal 2027 organic revenue guidance raised to 6%-9% from 4%-7% previously. Free cash flow surged 57% to $143 million in the first half, demonstrating strong cash conversion. Operating margin guidance revised down to 0-50 bps expansion due to capacity investment costs.
7 days agoHaemonetics stock hits 52-week high as CSL Plasma expands device rollout
Haemonetics shares rose 16.02% to $118.00, hitting a new 52-week high. CSL Plasma plans to deploy NexSys PCS devices across all US centers by end of 2027. Company maintains fiscal 2027 guidance pending finalization of deployment details. Further financial impact details expected during November 2026 earnings call.
1mo agoHaemonetics sets Q2FY27 earnings release date for November 5
Haemonetics Corporation will publish Q2 FY27 financial results on November 5, 2026. The company will hold an investor conference call at 8:00 am ET on the same day. A webcast replay will be available for one year starting November 5, 2026.
1mo agoHaemonetics signs CSL Plasma deal; shares hit 52-week high
Haemonetics Corp signed a non-exclusive deal with CSL Plasma to supply NexSys PCS devices in the US, with no minimum purchase commitments. Shares jumped 16.01% to $104.72, hitting a 52-week high, as BTIG raised its price target to $110. The company will update financial guidance in November 2026.
2mo agoJP Morgan raises Haemonetics price target to $86, keeps Neutral rating
JP Morgan analyst Allen Gong increased the price target for Haemonetics (NYSE: HAE) from $62 to $86. The firm kept its Neutral rating unchanged. This move reflects a higher valuation expectation for the blood management technology company.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in Haemonetics is now worth
$ 207.85
Giving a profit of
$ 107.85 (107.85%)
Note: Past profits do not guarantee future returns.
